SEC Form 4 · accession 0001209191-15-040022
Adamas Pharmaceuticals Inc · ADMS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Natalie McClure
Officer — SVP, Product Development
Period of report
May 5, 2015
Accepted (ET)
May 7, 2015 · 4:52 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001328143
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 5, 2015 | M | 2,000 | $1.755 | A | 2,840 | D | |
| Common StockF1 | May 5, 2015 | S | 2,000 | $17.62 | D | 840 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.755 | May 5, 2015 | M | 2,000 | D | — | Mar 3, 2020 | Common Stock | 2,000 | 14,666 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2This option is fully vested and exercisable.